Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxonidine for Antipsychotic-Induced Metabolic Side Effects
NCT01567124Phase 4Withdrawn
- Sponsor
- Baker Heart and Diabetes Institute
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of moxonidine in antipsychotic-induced weight gain (AIWG), sponsored by Baker Heart and Diabetes Institute. Planned start May 2012; status: withdrawn.
02
Drugs
moxonidine
03
Conditions
antipsychotic-induced weight gain (AIWG)
Beyond the preview
Go deeper on NCT01567124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01567124.